NCT02291783: Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment |
|
|
| Completed | 1 | 108 | Europe | HTL0009936, 9936, HTL0009936, HTL0009936 placebo, Placebo | Heptares Therapeutics Limited | Alzheimer's Disease | 07/14 | 07/14 | | |
NCT02710188: Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation |
|
|
| Completed | 1 | 14 | Europe | HTL0009936 modified release, HTL0009936 immediate release | Heptares Therapeutics Limited, Quotient Clinical | Alzheimer's Disease | 07/16 | 08/16 | | |
NCT02546310: Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects |
|
|
| Completed | 1 | 54 | Europe | HTL0009936, HTL0009936 matching placebo | Heptares Therapeutics Limited, P1vital Limited | Alzheimer's Disease | 02/17 | 02/17 | | |
